Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NEURONETICS, INC.

(STIM)
  Report
Delayed Nasdaq  -  04:00 2022-10-07 pm EDT
2.870 USD   -8.01%
09/27Neuronetics Launches Innovations To NeuroStar Advanced Therapy's Proprietary TrakStar Platform
AQ
09/26Neuronetics Launches Innovations To NeuroStar® Advanced Therapy's Proprietary TrakStar® Platform
GL
09/26Neuronetics Launches Innovations To NeuroStar® Advanced Therapy's Proprietary TrakStar® Platform
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Neurostar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

05/10/2022 | 08:31am EDT

Neuronetics, Inc. announced clearance from the U.S. Food and Drug Administration for its transcranial magnetic stimulation system as an adjunct for treating adult patients suffering from Obsessive-Compulsive Disorder. NeuroStar pioneered the TMS category as the first system FDA cleared for Major Depressive Disorder (MDD). NeuroStar is now leveraging the system's versatile coil design, which allows providers to treat both MDD and OCD without the need for additional hardware upgrades or purchases.

NeuroStar's proprietary cloud-based software, TrakStar, can remotely activate the new treatment protocol for providers once they are trained. Practice Development Managers and Clinical Training Managers will be available to deliver training to NeuroStar practices in the third quarter. This new indication will significantly add to NeuroStar's extensive Outcomes Registry, which is the larger outcomes registry in the world for depression.


© S&P Capital IQ 2022
All news about NEURONETICS, INC.
09/27Neuronetics Launches Innovations To NeuroStar Advanced Therapy's Proprietary TrakStar P..
AQ
09/26Neuronetics Launches Innovations To NeuroStar® Advanced Therapy's Proprietary TrakStar®..
GL
09/26Neuronetics Launches Innovations To NeuroStar® Advanced Therapy's Proprietary TrakStar®..
AQ
09/26Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary..
CI
09/13Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting ..
GL
09/13Neuronetics, Inc. Announces Grand Opening of Neurostar University with Ribbon-Cutting C..
CI
08/29Neuronetics Receives FDA Clearance for D-Tect Accessory Product
MT
08/29Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Adv..
GL
08/29Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Adva..
CI
08/26Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the ..
CI
More news
Analyst Recommendations on NEURONETICS, INC.
More recommendations
Financials (USD)
Sales 2022 61,8 M - -
Net income 2022 -43,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,92x
Yield 2022 -
Capitalization 84,3 M 84,3 M -
Capi. / Sales 2022 1,36x
Capi. / Sales 2023 1,15x
Nbr of Employees 175
Free-Float 96,1%
Chart NEURONETICS, INC.
Duration : Period :
Neuronetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEURONETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 3,12 $
Average target price 9,67 $
Spread / Average Target 210%
EPS Revisions
Managers and Directors
Keith J. Sullivan President, Chief Executive Officer & Director
Stephen Furlong Chief Financial Officer & Vice President-Finance
Robert A. Cascella Chairman
Cory Anderson VP-Clinical Affairs & Medical Operations
W. Andrew Macan Secretary, Chief Compliance Officer & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
NEURONETICS, INC.-30.04%84
THERMO FISHER SCIENTIFIC-18.13%211 797
DANAHER CORPORATION-15.49%202 266
INTUITIVE SURGICAL, INC.-44.98%70 601
BOSTON SCIENTIFIC CORPORATION-2.78%58 195
EDWARDS LIFESCIENCES CORPORATION-33.25%53 613